AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
ASTRAZENECA PHARMA | CIPLA | ASTRAZENECA PHARMA/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 134.3 | 35.6 | 377.0% | View Chart |
P/BV | x | 37.7 | 4.1 | 912.2% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
CIPLA Mar-20 |
ASTRAZENECA PHARMA/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 586 | 218.3% | |
Low | Rs | 883 | 357 | 247.4% | |
Sales per share (Unadj.) | Rs | 228.4 | 207.0 | 110.3% | |
Earnings per share (Unadj.) | Rs | 10.4 | 18.6 | 55.7% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 33.2 | 49.0% | |
Dividends per share (Unadj.) | Rs | 0 | 4.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 195.5 | 50.5% | |
Shares outstanding (eoy) | m | 25.00 | 806.35 | 3.1% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 4.7 | 2.3 | 207.8% | |
Avg P/E ratio | x | 104.2 | 25.3 | 411.4% | |
P/CF ratio (eoy) | x | 66.4 | 14.2 | 467.7% | |
Price / Book Value ratio | x | 10.9 | 2.4 | 453.8% | |
Dividend payout | % | 0 | 21.5 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 379,912 | 7.1% | |
No. of employees | `000 | 1.4 | 25.8 | 5.2% | |
Total wages/salary | Rs m | 1,535 | 30,270 | 5.1% | |
Avg. sales/employee | Rs Th | 4,210.9 | 6,459.6 | 65.2% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,171.2 | 96.7% | |
Avg. net profit/employee | Rs Th | 191.1 | 580.2 | 32.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 166,949 | 3.4% | |
Other income | Rs m | 123 | 3,442 | 3.6% | |
Total revenues | Rs m | 5,833 | 170,391 | 3.4% | |
Gross profit | Rs m | 463 | 32,060 | 1.4% | |
Depreciation | Rs m | 147 | 11,747 | 1.3% | |
Interest | Rs m | 0 | 1,974 | 0.0% | |
Profit before tax | Rs m | 438 | 21,782 | 2.0% | |
Minority Interest | Rs m | 0 | -475 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 6,312 | 2.8% | |
Profit after tax | Rs m | 259 | 14,995 | 1.7% | |
Gross profit margin | % | 8.1 | 19.2 | 42.2% | |
Effective tax rate | % | 40.8 | 29.0 | 140.9% | |
Net profit margin | % | 4.5 | 9.0 | 50.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 117,038 | 2.7% | |
Current liabilities | Rs m | 2,070 | 43,931 | 4.7% | |
Net working cap to sales | % | 20.0 | 43.8 | 45.6% | |
Current ratio | x | 1.6 | 2.7 | 58.2% | |
Inventory Days | Days | 72 | 96 | 75.6% | |
Debtors Days | Days | 35 | 85 | 41.0% | |
Net fixed assets | Rs m | 790 | 107,424 | 0.7% | |
Share capital | Rs m | 50 | 1,613 | 3.1% | |
"Free" reserves | Rs m | 2,419 | 156,018 | 1.6% | |
Net worth | Rs m | 2,469 | 157,630 | 1.6% | |
Long term debt | Rs m | 0 | 23,693 | 0.0% | |
Total assets | Rs m | 4,605 | 236,626 | 1.9% | |
Interest coverage | x | NM | 12.0 | - | |
Debt to equity ratio | x | 0 | 0.2 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.7 | 175.7% | |
Return on assets | % | 5.6 | 7.2 | 78.5% | |
Return on equity | % | 10.5 | 9.5 | 110.3% | |
Return on capital | % | 17.7 | 12.8 | 138.2% | |
Exports to sales | % | 0 | 33.0 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 55,175 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 56,036 | 0.5% | |
Fx outflow | Rs m | 2,015 | 6,764 | 29.8% | |
Net fx | Rs m | -1,715 | 49,272 | -3.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 30,685 | 0.3% | |
From Investments | Rs m | -94 | 1,040 | -9.0% | |
From Financial Activity | Rs m | NA | -29,488 | 0.0% | |
Net Cashflow | Rs m | -6 | 2,340 | -0.2% |
Indian Promoters | % | 0.0 | 16.0 | - | |
Foreign collaborators | % | 75.0 | 20.8 | 360.6% | |
Indian inst/Mut Fund | % | 0.3 | 12.2 | 2.5% | |
FIIs | % | 15.7 | 23.7 | 66.2% | |
ADR/GDR | % | 0.0 | 1.1 | - | |
Free float | % | 9.1 | 26.2 | 34.7% | |
Shareholders | 12,856 | 161,166 | 8.0% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: SUN PHARMA PROCTER & GAMBLE HEALTH GSK PHARMA UNICHEM LAB ORCHID PHARMA
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More